# NCT03267433 (NCT03267433)

> Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT03267433
- Phase: PHASE3
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: ECOG-ACRIN Cancer Research Group
- Conditions: Mantle Cell Lymphoma
- Interventions: Autologous Hematopoietic Stem Cell Transplantation; Biospecimen Collection; Bone Marrow Aspirate; Bone Marrow Biopsy; Computed Tomography; Positron Emission Tomography; Rituximab; Rituximab and Hyaluronidase Human
- Enrollment: 689
- Primary outcome: Overall survival (OS) in mantle cell lymphoma (MCL) patients in minimal residual disease (MRD)-negative complete remission (CR) who undergo auto-hematopoietic stem cell transplant (HCT) followed by rituximab versus (vs.) maintenance rituximab alone

## Commentary we found

- YouTube: 15
- X threads: 11
- Podcasts: 5

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=nct03267433

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT03267433", "email": "<work email>"}; the inbox owner confirms by the emailed link.